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Background. Development of hydroxyethyl starches (HES) with a low impact on blood
coagulation but a long intravascular persistence is of clinical interest. A previous in vitro study
showed that low substituted high molecular weight HES does not compromise blood coagulation
more than medium molecular weight HES. In the present study we assessed the individual effects
on blood coagulation of molar substitution and C2/C6 ratio of a high molecular weight HES.
Methods. Blood was obtained from 30 healthy patients undergoing elective surgery and mixed
with six high molecular weight (700 kDa) HES solutions differing in their molar substitution
(0.42 and 0.51) and C2/C6 ratio (2.7, 7 and 14) to achieve 20, 40 and 60% dilution. Blood
coagulation was assessed by Thrombelastograph analysis (TEG) and plasma coagulation tests.
Data were compared using a three-way analysis of variance model with repeated measures on the
three factors.
Results. Higher molar substitution compromised blood coagulation most (for all TEG
parameters, P<0.05). The lowest C2/C6 ratio was associated with the lowest effect on blood
coagulation; r (P<0.001), angle a (P=0.003) and coagulation index (P<0.001). No effect on k and
maximum amplitude was observed (P for both >0.50). The higher molar substitution was
associated with a lesser increase in PT (P=0.007) and a greater decrease in factor VIII
(P=0.010). PTT, functional and antigenic von Willebrand factors were not significantly influenced
by molar substitution (P for all >0.20). No significant differences between solutions with the same
molar substitution but different C2/C6 ratios were found in plasma coagulation parameters
(P for all >0.05).
Conclusions. TEG analysis indicates that high molecular HES with a molar substitution of 0.42
and a C2/C6 ratio of 2.7 has the lowest effect on in vitro human blood coagulation.
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Hydroxyethyl starches (HES) are widely used plasma
substitutes.1–4 The clinical use of HES is limited by its
impact on blood coagulation associated with a reduction
of circulating levels of factor VIII and von Willebrand
Factor (vWF) in a greater proportion than expected by
plasma dilution.5–7 Direct inhibition of platelet function
through binding of HES to the platelet surface may also
contribute to the blood coagulation compromising effects
of HES.4 8
HES is a modified branched natural polymer of amylo-
pectin. Besides its molecular weight, HES is characterized
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by its molar substitution, which expresses the average
number of hydroxethyl groups per unit of glucose, and by
the C2/C6 ratio, which describes more precisely the substi-
tution pattern: indeed, the hydroxyethyl units can be intro-
duced at positions 2, 3 and 6 of the glucose unit but most
frequently at positions C2 and C6, so that the C2/C6 ratio is
commonly indicated.2 4
There was a generally held view that low molecular
weight HES affects blood coagulation to a lesser extent
than high molecular HES. Indeed, studies comparing high
vs medium and low molecular weight HES confirmed this
advantage of medium and low molecular weight HES.5 9
However, in these studies, a reduction in molecular weight
has always been associated with a reduction in molar
substitution.
A preliminary in vitro study10 showed that two high
molecular HES solutions with a molar substitution of 0.4,
HES 500/0.4 and HES 800/0.4 (molecular weight/molar
substitution), had a slightly reduced effect on blood coagu-
lation compared with HES 200/0.5. In addition, an in vivo
study showed that, at low substitution, high molecular
weight HES did not compromise blood coagulation to a
greater extent than low molecular weight HES.11 We tested
the hypothesis that molar substitution might be a key
factor in determining the effect of a HES solution on
blood coagulation.
The present study assesses systematically the individual
effects of molar substitution and C2/C6 ratio and the
possibility of an interaction between these two parameters
on the reduced coagulation produced by high molecular
weight HES.
Materials and methods
This study of 30 patients was approved by our local ethics
committee and each patient gave written informed consent.
Patients between 18 and 80 yr of age undergoing various
surgical procedures were enrolled. Exclusion criteria were
emergency surgery, a history of preoperative coagulation
disorders, anticoagulation, treatment with acetylsalicylic
acid or nonsteroidal anti-inflammatory drugs within 5 days
before surgery, history of renal dysfunction or increased
serum creatinine levels (>120 mmol litre1), history of
liver dysfunction or increased plasma levels of aspartate
aminotransferase (>50 u litre1) or alanine aminotransferase
(> 50 u litre1), treatment with HES solutions within 30 days
before surgery and ASA III or IV classification as judged
by the responsible anaesthesiologist. A standard prophylaxis
of 3000 u of s.c. low molecular weight heparin the day
before surgery was allowed.
Eighty millilitres of blood was removed from an antecu-
bital vein by direct venipuncture using a 19 gauge butterfly
connected to 10 ml monovettes containing 3.13% trisodium
citrate (S-Monovette 10 ml 9 NC, Sarstedt, Nu¨mbrecht,
Germany). The first 10 ml of blood was discarded to
avoid activation of blood coagulation.
The blood from eight citrated monovettes was added into
one polystyrene tube to produce one homogenous sample,
and the whole blood was then incubated at 37C for 1 h.12
The blood was then diluted. All 18 different possible
dilutions (six different HES solutions at three dilutions;
see Fig. 1) were initially made with one blood sample
using blinded HES solutions labelled A, B, C, D, E and
F. The diluted samples were again maintained for 1 h at
37C in an incubator.12
TEG analysis was performed using two computerized
Thrombelastograph coagulation analysers 5000 (TEG,
Haemoscope Corporation, Niles, IL, USA). Four samples
were analysed at a time and the sequences of analysis and
the TEG channels were randomly chosen for each patient
using the randomly permuted blocks method. One millilitre
of diluted blood was added to a tube containing 1% kaolin.
The tube was mixed and an aliquot of 340 ml kaolin
activated blood was then placed into the TEG cup contain-
ing 20 ml of 2 M CaCl2. TEG analysis started immediately.
Haemoglobin concentration was determined with a blood
gas analyser (Bayer Diagnostic Ltd, model 865, Bayer,
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Fig 1 Design of the trial: the blood was diluted at 20, 40 and 60% with each of the six blinded solutions (A, B, C, D, E and F) in polystyrene tubes
yielding 5 ml of blood–HES mixtures.
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Zu¨rich, Switzerland) using arterial blood samplers contain-
ing lyophilized lithium heparin (Marquest Quik A.B.G.,
Englewood, CO, USA).
For prothrombin time (PT), activated partial throm-
boplastin time (aPTT), factor VIII and vWF measurements,
samples were centrifuged at 3000 rpm for 15 min at 4C
(Rotanta/RP, Hettich, Ba¨ch, Switzerland). PT and aPTT
were determined on an automated coagulation analyser
(BCS, Dade Behring, Marburg, Germany) using a PT
reagent containing recombinant tissue factor (Innovin,
Dade Behring) and an aPTT reagent containing ellagic
acid (Actin FS, Dade Behring), respectively. Factor VIII
was assessed functionally using factor VIII-deficient plasma
(Helena Haemostasis Systems Ltd, Sunderland, Tyne and
Wear, UK). Functional activity of vWF was determined in a
commercial ristocetin-cofactor assay (vWF RCA, Dade
Behring) on an automated coagulation analyser (BCS,
Dade Behring). Briefly, vWF activity was assessed by the
ability to agglutinate fixed human platelets in the presence
of ristocetin. Agglutination was turbidimetrically measured
by the coagulation analyser. Antigenic vWF levels were
assayed by a commercial ELISA kit (Asserachrom vWF
antigenic, Roche Diagnostics, Rotkreuz, Switzerland)
according to the manufacturer’s instructions.
HES syntheses
Thin-boiling waxy maize starch was suspended in water,
activated by means of sodium hydroxide, and allowed to
react with ethylene oxide for 2 h at 40C. The amounts of
waxy maize starch and ethylene oxide were chosen to yield
HES with molar substitutions of 0.42 and 0.51. HES C2/C6
ratios of 2.7, 7 and 14 were obtained by changing the quant-
ities of sodium hydroxide during hydroxyethylation. All raw
HES species were hydrolysed by hydrochloric acid to
molecular weights of 700 kDa, treated with activated car-
bon, purified by ultra-filtration and diluted to a final con-
centration of 6% (w/v) in isotonic saline, filled in glass
bottles of 500 ml each, and heat-sterilized at 121C for
20 min. HES synthesis was performed in the laboratories
of B. Braun Medical SA, Crissier, Switzerland.
HES characterization
Mean molecular weight (Mw) of HES was determined by
GPC-MALLS (Wyatt Technology, Woldert, Germany) at a
flow rate of 1 ml min1 in a 70 mM phosphate buffer pH 7.0
using serial GPC columns HEMA Bio 40, 100 and 1000
(PSS, Mainz, Germany). Mw was calculated using ASTRA
Software (Wyatt Technology, Woldert, Germany).
Molar substitution was determined by gas chromato-
graphy after transforming hydroxyethyl groups into ethyl
iodine by hydriodic acid in the presence of adipic acid
using a gas chromatograph (Perkin Elmer Autosystem;
Boston, MA, USA). C2/C6 ratio was determined after
hydrolysis of HES by sulphuric acid and gas chromato-
graphic separation of the silylated hydroxyethylated glucose
derivatives using a gas chromatograph (Carlo Erba Mega
5300; Milan, Italy).
Statistical analysis
Sample size has been determined by a power analysis based
on a previous in vitro study.10 To obtain a power of 80%
with an estimated difference between groups of 10% and a
SD of 15% a total sample size of 30 patients has been determ-
ined with a type I error of 0.05.
All data were calculated as changes vs baseline and repor-
ted as mean (SD). A three-way analysis of variance model
with repeated measures on three ways was constructed using
the JMP 5.1 statistical package (SAS Institute, Inc., Cary,
NC) for assessing the effect of molar substitution, C2/C6
ratio and dilution, respectively, and all possible interaction
between these factors. Thus, the variability was partitioned
into the following components: molar substitution, C2/C6
ratio, interaction between molar substitution and C2/
C6 ratio, dilution, interaction between dilution and C2/C6
ratio, interaction between dilution and molar substitution,
and interaction between all three factors.
Results
Plasma coagulation and TEG parameters were normal at
baseline (Table 1).
Dilution effect
Haemoglobin decreased from 12.2 (1.3) to 9.8 (1.2) g dl1
(20% dilution), 7.6 (1.0) g dl1 (40% dilution) and
5.2 (0.8) g dl1 (60% dilution) because of in vitro haemodi-
lution (P<0.001). No difference was found between the
different HES solutions investigated. Dilution alone had a
significant effect on all TEG parameters and on all plasma
coagulation parameters (P<0.001 for all parameters): the
more the blood was diluted, the more the coagulation
was compromised (see Figs 2–5).
Table 1 Baseline values. Data are mean (SD). The following parameters were
measured: TEG: r-time, k-time, angle a, MA, shear elastic modulus (G) and CI;
plasma coagulation: PT, aPTT, functional vWF and antigenic vWF (AG vWF)
and factor VIII (F VIII)
Normal range
TEG parameters
r-time (mm) 9.9 (1.1) 5–15
k-time (mm) 3.1 (0.7) 2–6
Angle a () 67.6 (4.2) 55–78
MA (mm) 62.0 (7.4) 51–69
G (Kd s1) 9.0 (2.4) 4.6–10.9
CI 1.2 (1.4) 3 to 3
Plasma coagulation
PT (s) 10.1 (0.7) 7.7–11
PTT (s) 32.4 (3.2) 26–36
Functional vWF (%) 97.2 (39.9) 50–200
AG vWF (%) 139.8 (57.9) 50–200
F VIII (%) 89.5 (27.9) 50–200
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Molar substitution effect
TEG
The higher molar substitution of 0.51 resulted in a greater
compromise in blood coagulation for all TEG
parameters: r-time (P<0.001) and k-time (P=0.031) were
prolonged more when diluted using a HES solution with
a molar substitution of 0.51 than when diluted using a
HES solution with a molar substitution of 0.42 (Fig. 2A
and B). Angle a (P=0.008), maximal amplitude (MA)
(P=0.013), G (P=0.003) and coagulation index (CI)
(P=0.007) showed a stronger decrease when diluted with
a HES solution with a molar substitution of 0.51 than when
diluted with a HES solution with a molar substitution of 0.42
(Fig. 2C–F).
Plasma coagulation
PT (P=0.007) increase was lower and factor VIII (P=0.010)
decrease was greater when diluted using a HES solution
with a molar substitution of 0.51 than when diluted using
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Fig 2 Effects of molar substitution (MS) on TEG analysis. Blood samples were diluted with HES solutions with a MS 0.42 or 0.51 at dilutions of
20% (Dil_20), 40% (Dil_40) and 60% (Dil_60). The following TEG parameters were measured: r-time (A), k-time (B), angle a (C), MA (D), shear
elastic modulus (G) (E) and CI (F). Mean (SD) changes vs baseline are depicted (n=30).
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a HES solution with a molar substitution of 0.42 (Fig. 3A
and B) while aPTT (P=0.213), functional and antigenic
vWFs (P=0.782 and 0.296, respectively) showed no signi-
ficant differences when diluted using HES solutions with
a molar substitution of 0.51 or 0.42 (Fig. 3C–E).
C2/C6 ratio effect
TEG
HES solutions with different C2/C6 ratios affected r-time
(P<0.001), angle a (P=0.003) and CI (P<0.001) (Fig. 4A–C),
while there were no significant differences between these
solutions for k-time (P=0.513), MA (P=0.699) and G
(P=0.246) (Fig. 4D–F).
Plasma coagulation
No significant differences between solutions with different
C2/C6 ratios was found concerning PT (P=0.061), factor
VIII (P=0.099), aPTT (P=0.086), functional and antigenic
vWFs (P=0.916 and 0.064, respectively) (Fig. 5).
Interactions
A significant interaction between molar substitution and C2/
C6 ratio was found for r-time, angle a and CI (all P<0.001).
–120
–100
–80
–60
–40
–20
0
0
2
4
6
8
10
12
–100
–80
–60
–40
–20
0
0
20
40
60
∆ PT (s) ∆ Factor VIII (%)
∆ aPTT (s) ∆ Functional vWF (%)
A B
C D
E
pMS=0.007
–200
–150
–100
–50
0
∆  AG vWF (%)
MS=0.42
MS=0.51
MS=0.42
MS=0.51
MS=0.42
MS=0.51
Dil_20 Dil_40 Dil_60
Dil_20 Dil_40 Dil_60
Dil_20 Dil_40 Dil_60
pMS=0.010
Dil_20 Dil_40 Dil_60
pMS=0.782
MS=0.42
MS=0.51
pMS=0.213
Dil_20 Dil_40 Dil_60
pMS=0.296
MS=0.42
MS=0.51
Fig 3 Effects of molar substitution (MS) on plasma coagulation. Blood samples were diluted with HES solutions with a MS 0.42 or 0.51 at
dilutions of 20% (Dil_20), 40% (Dil_40) and 60% (Dil_60). The following plasma coagulation parameters were measured: PT (A), factor VIII (B),
aPTT (C), functional vWF (D) and antigenic vWF (E). Mean (SD) changes vs baseline are depicted (n=30).
HES characteristics and blood coagulation
459
At a molar substitution of 0.42, k-time was progressively
prolonged and angle a and CI were progressively reduced
with increasing C2/C6 ratios (Fig. 6). In contrast, at a molar
substitution of 0.51, a C2/C6 ratio of 7 resulted in a max-
imum compromise of blood coagulation (Fig. 6). No signi-
ficant interaction was found for k-time (P=0.786), MA
(P=0.696), G (P=0.489), PT (P=0.343), factor VIII
(P=0.874), aPTT (P=0.237), functional and antigenic
vWFs (P=0.865 and 0.821, respectively).
Discussion
This study indicates that HES 700/0.42/2.7 (molecular
weight/molar substitution/C2/C6 ratio) has a less
pronounced effect on in vitro human blood coagulation
than HES solutions of the same molecular weight with a
higher degree of molar substitution and a higher C2/C6
ratio.
Molecular weight has been considered for a long time as a
key factor in determining the compromising effects of HES
on blood coagulation.1 2 However, in recent years the devel-
opment of HES was always characterized by a concomitant
reduction in molecular weight and molar substitution
whereas the isolated effect of the molecular weight has
not been systematically examined. Only recently Madjdpour
and colleagues11 tested HES molecules with different
molecular weights but identical molar substitution.
They found that, at a low molar substitution (0.42), high
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Fig 4 Effects of C2/C6 ratio on TEG analysis. Blood samples were diluted with HES solutions with C2/C6 ratio of 2.7, 7 or 14 at dilutions of 20%
(Dil_20), 40% (Dil_40) and 60% (Dil_60). The following TEG parameters were measured: r-time (A), angle a (B), CI (C), k-time (D), MA (E) and
shear elastic modulus (G) (F). Mean (SD) changes vs baseline are depicted (n=30).
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molecular weight HES does not compromise blood coagu-
lation to a greater extent than low molecular weight HES
with the same molar substitution.
Treib and colleagues13 studied the effect of molar sub-
stitution on blood coagulation. They showed that a HES
200/0.62 solution affected coagulation of human blood
more than HES 200/0.5. Unfortunately, the C2/C6 ratio
of the solutions used was not indicated. Furthermore,
only plasma coagulation but not TEG analyses have been
performed with the latter providing a complementary view
on the process of blood coagulation by testing the kinetics of
the whole coagulation process.14
An in vitro study investigated the effect of HES 70/0.5/
3.2, HES 130/0.4/11.2 and HES 200/0.5/4.6 solutions on
blood coagulation and found a reduced effect on blood
coagulation of HES 130/0.4/11.2.15 The authors postulated
that the smaller molar substitution might be responsible for
this beneficial effect. However, in this study, molecular
weight, molar substitution and C2/C6 ratio varied consid-
erably. Thus, it is difficult to allocate precisely an effect to
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Fig 5 Effects of C2/C6 ratio on plasma coagulation. Blood samples were diluted with HES solutions with C2/C6 ratio of 2.7, 7 or 14 at dilutions of
20% (Dil_20), 40% (Dil_40) and 60 % (Dil_60). The following plasma coagulation parameters were measured: PT (A), factor VIII (B), aPTT (C),
functional vWF (D) and antigenic vWF (E). Mean (SD) changes vs baseline are depicted (n=30).
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one parameter. Interestingly, Niemi and Kuitunen16 recently
found in an in vitro study that HES 120/0.7 compromised
blood coagulation less than HES 130/0.4. Unfortunately, the
C2/C6 ratio was not described.
This illustrates the need for systematic studies, which may
only be possible in vitro, elucidating the complex interplay
between molecular weight, molar substitution and the C2/
C6 ratio on the effect of HES on blood coagulation. In such a
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Fig 6 TEG parameters for which a significant interaction between molar substitution (MS) and C2/C6 ratio was found for HES solutions with a
MS of 0.42 (left) or a MS of 0.51 (right) at dilutions of 20% (Dil_20), 40% (Dil_40) and 60% (Dil_60): r-time (A and B), angle a (C and D) and CI
(E and F). Mean (SD) changes vs baseline are depicted (n=30).
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study, we have now found that in high molecular HES a
molar substitution of 0.42 and a C2/C6 ratio of 2.7 results in
slightly reduced in vitro blood coagulation compromising
effects. The observed differences are obviously small but the
study design allowed paired comparisons and had thus the
power to detect even minor differences. Extrapolating this
finding to clinical practice is fraught with difficulties and
certainly requires confirmatory in vivo studies. Also the
effect of the relatively low C2/C6 ratio on pharmacokinetics
needs to be equally assessed in vivo.
Prophylactic s.c. low-molecular weight heparin does not
modify TEG parameters.17 This is in keeping with the find-
ing that baseline TEG parameters were in the normal range
in this study (Table 1), as they were in several previous
studies.12 18 19
The ideal properties of a HES solution may differ between
the intraoperative and the postoperative period. Intraoper-
atively, a minimal effect on blood coagulation is certainly
important. A longer intravascular retention time may be
desirable after operation, whereas a certain blood coagula-
tion compromising effect may not necessarily be deleteri-
ous. In fact, McCrath and colleagues20 have recently shown
that patients already with a minimal hypercoagulability at
the end of surgery had a higher incidence of major throm-
boembolic complications such as ischaemic strokes,
myocardial infarctions, deep venous thrombosis and venous
thromboembolism after operation despite standard throm-
boembolic prophylaxis.
In conclusion, a molar substitution of 0.42 and a C2/C6
ratio of 2.7 were found to be associated with the least com-
promise on blood coagulation in high molecular (700 kDa)
HES. Further studies are necessary to assess whether such
a HES also compromises in vivo blood coagulation
minimally and whether its intravascular retention is indeed
higher than a low molecular, low substituted HES such as a
HES 130/0.42.
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